Trial Profile
A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 May 2023
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Adenocarcinoma; Bone metastases; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms ALSYMPCA
- Sponsors Algeta; Bayer
- 25 May 2023 According to a Bayer media release, data from this study will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6, 2023.
- 21 Sep 2020 Results of post-hoc analysis investigating the role of NLR, neutrophilia and lymphopenia on the outcome of mCRPC patients treated with Ra-223 presented at the 45th European Society for Medical Oncology Congress
- 27 Aug 2020 According to a Bayer media release, Chinese National Medical Products Administration (NMPA) has approved Xofigo(radium-223 dichloride) for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastases. The approval of Xofigo in China is based on the ALSYMPCA data as well as the NCT01810770 trial operated in Asia.